4565Sosei Group Corporation4565 info
$9.11info2.69%24h
Global rank9189
Market cap$749.75M
Change 7d2.12%
YTD Performance-8.84%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Sosei Group Corporation (4565) Stock Overview

    Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.

    4565 Stock Information

    Symbol
    4565
    Address
    PMO HanzomonTokyo, 102-0083Japan
    Founded
    -
    Trading hours
    -
    Website
    https://soseiheptares.com
    Country
    🇯🇵 Japan
    Phone Number
    81 3 5210 3290

    Sosei Group Corporation (4565) Price Chart

    -
    Value:-

    Sosei Group Corporation Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $9.11
    N/A
    Market Cap
    $749.75M
    N/A
    Shares Outstanding
    82.34M
    N/A
    Employees
    348.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org